Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors: From Risk Factors to Clinical Outcomes
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors: From Risk Factors to Clinical Outcomes
Authors
Keywords
-
Journal
POSTGRADUATE MEDICINE
Volume 125, Issue 3, Pages 7-20
Publisher
Informa UK Limited
Online
2013-06-07
DOI
10.3810/pgm.2013.05.2659
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors
- (2013) M. Barbieri et al. ATHEROSCLEROSIS
- Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
- (2013) Samuel S Engel et al. Cardiovascular Diabetology
- Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non- diabetic subjects: a preliminary report
- (2013) Yoko Noda et al. Cardiovascular Diabetology
- Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, Improves Endothelial Dysfunction in Association With Its Anti-Inflammatory Effects in Patients With Coronary Artery Disease and Uncontrolled Diabetes
- (2013) Junichi Matsubara et al. CIRCULATION JOURNAL
- Sitagliptin improves beta-cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities-the BEGAMI study
- (2013) C. Hage et al. JOURNAL OF INTERNAL MEDICINE
- Cardiovascular effects of gliptins
- (2013) André J. Scheen Nature Reviews Cardiology
- A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus
- (2013) Jorge Luiz Gross et al. BMJ Open
- DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis
- (2012) Matteo Monami et al. ADVANCES IN THERAPY
- Clinical Implications of Cardiovascular Preventing Pleiotropic Effects of Dipeptidyl Peptidase-4 Inhibitors
- (2012) Steven G. Chrysant et al. AMERICAN JOURNAL OF CARDIOLOGY
- Meta-Analysis of Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Risk in Type 2 Diabetes Mellitus
- (2012) Harshal R. Patil et al. AMERICAN JOURNAL OF CARDIOLOGY
- Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: Meta-Analysis
- (2012) Haesuk Park et al. ANNALS OF PHARMACOTHERAPY
- Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
- (2012) Michael E Cobble et al. Cardiovascular Diabetology
- Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
- (2012) Odd Johansen et al. Cardiovascular Diabetology
- Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin
- (2012) Yan-Ling He CLINICAL PHARMACOKINETICS
- Incretin-based therapies and cardiovascular risk
- (2012) Edoardo Mannucci et al. CURRENT MEDICAL RESEARCH AND OPINION
- Cardiovascular effects of the DPP-4 inhibitors
- (2012) Tessey Jose et al. Diabetes & Vascular Disease Research
- Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of dipeptidyl peptidase-IV inhibition
- (2012) M. R. Rizzo et al. DIABETES CARE
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETES CARE
- Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis
- (2012) S.-C. Liu et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials
- (2012) M. Monami et al. DIABETES OBESITY & METABOLISM
- The Effect of Sitagliptin Versus Glibenclamide on Arterial Stiffness, Blood Pressure, Lipids, and Inflammation in Type 2 Diabetes Mellitus Patients
- (2012) Shlomit Koren et al. Diabetes Technology & Therapeutics
- The incretin hormones: from scientific discovery to practical therapeutics
- (2012) S. Mudaliar et al. DIABETOLOGIA
- Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study
- (2012) B. Eliasson et al. DIABETOLOGIA
- Saxagliptin
- (2012) Lily P.H. Yang DRUGS
- Cardiovascular Biology of the Incretin System
- (2012) John R. Ussher et al. ENDOCRINE REVIEWS
- Alogliptin benzoate for the treatment of type 2 diabetes
- (2012) Marc Rendell et al. EXPERT OPINION ON PHARMACOTHERAPY
- Sitagliptin Exerts an Antinflammatory Action
- (2012) Antoine Makdissi et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Improves Vascular Endothelial Function in Type 2 Diabetes
- (2012) Yoshiaki Kubota et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- Reduced CD26 expression is associated with improved cardiac function after acute myocardial infarction
- (2012) Simone Post et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Dipeptidyl Peptidase-4 Inhibitor
- (2012) Toyoaki Murohara JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- A Dipeptidyl Peptidase-4 Inhibitor, Des-Fluoro-Sitagliptin, Improves Endothelial Function and Reduces Atherosclerotic Lesion Formation in Apolipoprotein E–Deficient Mice
- (2012) Junichi Matsubara et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies
- (2012) Nancy J. Brown Journal of the American Society of Hypertension
- 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
- (2012) Baptist Gallwitz et al. LANCET
- A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients
- (2012) Noriko Satoh-Asahara et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury
- (2012) Veerle Matheeussen et al. PHARMACOLOGY & THERAPEUTICS
- Sitagliptin: Anti-platelet effect in diabetes and healthy volunteers
- (2012) Ashish Kumar Gupta et al. PLATELETS
- The Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus: Cardiovascular Safety
- (2012) Jennifer B. Green POSTGRADUATE MEDICINE
- Reappraisal of Metformin Efficacy in the Treatment of Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials
- (2012) Rémy Boussageon et al. PLOS MEDICINE
- The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus–Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study
- (2011) Benjamin M. Scirica et al. AMERICAN HEART JOURNAL
- EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE)
- (2011) William B. White et al. AMERICAN HEART JOURNAL
- Ongoing Clinical Trials Evaluating the Cardiovascular Safety and Efficacy of Therapeutic Approaches to Diabetes Mellitus
- (2011) Vivian A. Fonseca AMERICAN JOURNAL OF CARDIOLOGY
- Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins
- (2011) Sameer Ansar et al. Cardiovascular Diabetology
- Cardiovascular Implications of Antihyperglycemic Therapies for Type 2 Diabetes
- (2011) Fernando Ovalle CLINICAL THERAPEUTICS
- Impact of weight gain on outcomes in type 2 diabetes
- (2011) Stuart A. Ross et al. CURRENT MEDICAL RESEARCH AND OPINION
- Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states
- (2011) Sarah Farr et al. CURRENT OPINION IN LIPIDOLOGY
- The role of incretins in salt-sensitive hypertension
- (2011) Tetsuhiro Tanaka et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials
- (2011) A.J. Scheen DIABETES & METABOLISM
- Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes
- (2011) P. C. M. van Poppel et al. DIABETES CARE
- The Possible Protective Role of Glucagon-Like Peptide 1 on Endothelium During the Meal and Evidence for an "Endothelial Resistance" to Glucagon-Like Peptide 1 in Diabetes
- (2011) A. Ceriello et al. DIABETES CARE
- Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes
- (2011) A. Chaudhuri et al. DIABETES OBESITY & METABOLISM
- Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes
- (2011) A. J. Tremblay et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase-4 inhibitors and HbA1c target of
- (2011) K. Esposito et al. DIABETES OBESITY & METABOLISM
- Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials
- (2011) Matteo Monami et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Linagliptin
- (2011) Lesley J. Scott DRUGS
- Pharmacology of Dipeptidyl Peptidase-4 Inhibitors
- (2011) Roberta Baetta et al. DRUGS
- A review of gliptins in 2011
- (2011) André J Scheen EXPERT OPINION ON PHARMACOTHERAPY
- Management of type 2 diabetes: new and future developments in treatment
- (2011) Abd A Tahrani et al. LANCET
- Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- The Pharmacologic Basis for Clinical Differences among GLP-1 Receptor Agonists and DPP-4 Inhibitors
- (2011) Javier Morales POSTGRADUATE MEDICINE
- Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Decreases Systolic Blood Pressure in Japanese Hypertensive Patients with Type 2 Diabetes
- (2011) Susumu Ogawa et al. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
- Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1
- (2011) Gian Paolo Fadini et al. VASCULAR PHARMACOLOGY
- Effects of incretins on blood pressure: A promising therapy for type 2 diabetes mellitus with hypertension
- (2011) Bin WANG et al. Journal of Diabetes
- DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients With Coronary Artery Disease
- (2010) Philip A. Read et al. Circulation-Cardiovascular Imaging
- The Cardiovascular Effects of Metformin: Further Reasons to Consider An Old Drug as a Cornerstone in the Therapy of Type 2 Diabetes Mellitus
- (2010) Giovanni Anfossi et al. Current Vascular Pharmacology
- Weight Loss, Glycemic Control, and Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort Database
- (2010) E. S. Horton et al. DIABETES CARE
- The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes: Possible role of stromal-derived factor-1
- (2010) G. P. Fadini et al. DIABETES CARE
- Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population
- (2010) A. Schweizer et al. DIABETES OBESITY & METABOLISM
- Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control
- (2010) P. Anagnostis et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
- (2010) André J. Scheen et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Alogliptin
- (2010) Lesley J. Scott DRUGS
- Sitagliptin
- (2010) Sohita Dhillon DRUGS
- Vildagliptin
- (2010) Gillian M. Keating DRUGS
- Sitagliptin reduces albuminuria in patients with type 2 diabetes [Rapid Communication]
- (2010) Sachiko Hattori ENDOCRINE JOURNAL
- Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans
- (2010) Annis Marney et al. HYPERTENSION
- Dipeptidyl Peptidase IV Inhibition Alters the Hemodynamic Response to Angiotensin-Converting Enzyme Inhibition in Humans With the Metabolic Syndrome
- (2010) Edwin K. Jackson HYPERTENSION
- Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial) — Rationale, design and first interim analysis
- (2010) Hans D. Theiss et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes
- (2010) Olivia J. Phung JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Regulatory Action on Rosiglitazone by the U.S. Food and Drug Administration
- (2010) Janet Woodcock et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Meta-Analysis of Placebo-Controlled Clinical Trials Assessing the Efficacy and Safety of Incretin-Based Medications in Patients with Type 2 Diabetes
- (2010) Walid K.H. Fakhoury et al. PHARMACOLOGY
- Type 2 Diabetes Comorbidities and Treatment Challenges: Rationale for DPP-4 Inhibitors
- (2010) Priscilla A. Hollander et al. POSTGRADUATE MEDICINE
- A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes
- (2010) Robert Frederich et al. POSTGRADUATE MEDICINE
- Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
- (2010) Debora Williams-Herman et al. BMC Endocrine Disorders
- Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?
- (2009) David J Grieve et al. BRITISH JOURNAL OF PHARMACOLOGY
- Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay
- (2009) Kevin Niswender DIABETES OBESITY & METABOLISM
- Diabetes medications and body weight
- (2009) Joanna Mitri et al. Expert Opinion On Drug Safety
- Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors
- (2009) Manfredi Rizzo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin—based therapies
- (2009) Kiwon Ban et al. Journal of the American Society of Hypertension
- Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients
- (2009) Giuseppe Derosa et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Antidiabetic agents and cardiovascular risk in type 2 diabetes
- (2009) Stuart W. Zarich Nature Reviews Endocrinology
- Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials
- (2009) M. Monami et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Robust improvements in fasting and prandial measures of β-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database
- (2008) R. E. Pratley et al. DIABETES OBESITY & METABOLISM
- Hypoglycaemia in Type 2 diabetes
- (2008) S. A. Amiel et al. DIABETIC MEDICINE
- Dipeptidyl-Peptidase-IV Inhibition Augments Postprandial Lipid Mobilization and Oxidation in Type 2 Diabetic Patients
- (2008) Michael Boschmann et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effect of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate Hypertension
- (2008) Goutam C. Mistry et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies
- (2008) Theodore Mazzone et al. LANCET
- Assessing the Cardiovascular Safety of Diabetes Therapies
- (2008) Allison B. Goldfine NEW ENGLAND JOURNAL OF MEDICINE
- The Role of Incretins in Glucose Homeostasis and Diabetes Treatment
- (2008) W. Kim et al. PHARMACOLOGICAL REVIEWS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started